A Study of Invikafusp Alfa (STAR0602), a Selective T Cell Receptor (TCR)-Targeting, Bifunctional Antibody-fusion Molecule, in Combination With Sacituzumab Govitecan in Participants With Advanced Solid Tumors

This study is testing a new combination of two cancer treatments — Invikafusp Alfa (an experimental drug that activates immune T cells) and sacituzumab govitecan (an antibody-drug conjugate) — for people with advanced breast cancer that has not responded to prior treatments. **You may be eligible if...** - You have advanced or metastatic triple-negative breast cancer (TNBC) or hormone receptor-positive, HER2-negative breast cancer that has progressed or come back - Your cancer is measurable on a scan - If you have brain metastases, they must have been treated and be stable for at least 14 days **You may NOT be eligible if...** - You have active, untreated brain metastases causing symptoms - You have received certain prior treatments that overlap with this regimen (specific restrictions apply based on your cancer subtype) - You have significant other health conditions that could interfere with safety Talk to your doctor to see if this trial is right for you.